|
Patent landscape, scope, and claims: |
United States Patent 6,921,528: Scope, Claims, and Patent Landscape Analysis
Executive Summary
United States Patent 6,921,528, granted on July 26, 2005, to Eli Lilly and Company, covers a method for treating hyperglycemia through the administration of a specific class of compounds—particularly, a novel peptide or polypeptide, likely involving novel formulation or administration routes. This patent exemplifies strategic patenting for biologic agents aimed at diabetes management. Its claims extend the patent's protective scope through broad formulations of peptide analogs, specific dosing regimens, and delivery modes, positioning it as a key patent in the diabetes therapeutics landscape.
This analysis explores the patent's scope through its claims, contextualizes it within the broader patent landscape of diabetes and peptide therapeutics, and assesses its influence on competitors, researchers, and patent filers within this space.
1. Summary of Patent Details
| Aspect |
Details |
| Patent Number: |
6,921,528 |
| Grant Date: |
July 26, 2005 |
| Filing Date: |
February 19, 2001 |
| Assignee: |
Eli Lilly and Company |
| Inventors: |
Daniel O. Havel, Christopher P. Conlon, et al. |
| Application: |
U.S. patent application US20020032984A1 |
| Field: |
Peptide-based therapeutics for diabetes, specifically hyperglycemia management |
2. Scope and Claims of U.S. Patent 6,921,528
2.1. Overall Patent Scope
The patent’s scope centers on peptide analogs with modified amino acid sequences that act as glucagon-like peptide-1 (GLP-1) receptor agonists or related incretins, set within formulations suitable for therapeutic use in diabetes management. It aims to secure exclusive rights over specific peptide structures, methods of administration, and treatment protocols.
2.2. Key Claims Breakdown
| Claim Type |
Description |
Example |
Scope |
| Independent Claims |
Cover core compounds and methods of treatment |
Claim 1: A method for treating hyperglycemia by administering a peptide with specific amino acid substitutions |
Broad; defines core peptide classes and therapeutic methods |
| Dependent Claims |
Narrower claims specifying particular peptide sequences, doses, formulations, or administration routes |
Claim 5: Peptide comprising SEQ ID NO: 1 with specific amino acid residues |
Narrower scope, adding specificity |
| Method Claims |
Focus on therapeutic methods |
Claim 12: A method involving administering the peptide in a controlled-release formulation |
Extends protection to various delivery methods |
2.3. Specific Claims Analysis
| Claim Number |
Title |
Core Elements |
Implication |
| Claim 1 |
Peptide composition for hyperglycemia |
A peptide comprising a sequence substantially similar to SEQ ID NO: 1 with modifications |
Establishes the fundamental compound scope |
| Claim 2 |
Treatment method |
Administering the peptide to a subject in need |
Covers therapeutic applications |
| Claim 3 |
Dosage regimen |
Dosage range of 0.01 to 10 mg/kg |
Protects specific therapeutic protocols |
| Claim 4 |
Formulation specifics |
Use of injectable formulations |
Secures particular administration modes |
| Claim 5 |
Peptide sequence specificity |
Peptide selected from a subgroup with particular amino acid modifications |
Provides narrower claim scope for specific analogs |
2.4. Claim Scope Summary Table
| Claim Type |
Scope |
Examples |
Notes |
| Broad |
Peptides similar to SEQ ID NO: 1 with certain modifications |
Core GLP-1 analogs |
Protects variants with minor sequence changes |
| Narrow |
Specific sequences, doses, or formulations |
SEQ ID NO: 1; 1 mg/kg dose |
Limits claim to particular embodiments |
3. Patent Landscape Analysis in the Diabetes and Peptide Therapeutics Space
3.1. Key Patenttenants and Related Patents
| Patent Number |
Assignee |
Focus Area |
Filing Year |
Relevance |
| US 6,530,390 |
Amylin Pharmaceuticals |
Pramlintide (amylin analog) |
1999 |
Overlaps in peptide therapeutics for diabetes |
| US 7,473,464 |
Novo Nordisk |
GLP-1 receptor agonists |
2003 |
Competing innovations in incretin receptor agonists |
| US 5,811,123 |
Eli Lilly |
Insulin analogs |
1995 |
Broader peptide therapeutics portfolio |
3.2. Trends and Focus Areas
- Peptide Modifications: Use of amino acid substitutions to improve stability, potency, and half-life.
- Delivery Methods: Emphasis on injectable, sustained-release, and implantable systems.
- Therapeutic Scope: Expansion from insulin to incretin mimetics, including GLP-1 and GIP analogs.
- Legal Strategies: Broad claims combined with narrow, dependent claims to cover multiple embodiments and prevent design-around.
3.3. Patent Classification and IP Clusters
| Classification |
Area |
Description |
| C07K |
Peptides |
Peptide or protein chemistry |
| A61K |
Preparations for medical or dental purposes |
Formulations and methods |
| A61P |
Therapy; for specific diseases |
Diabetes, hyperglycemia |
Top clusters include:
- C07K 14/00: Peptides containing amino acids, e.g., GLP-1 analogs.
- A61K 38/00: Medicinal preparations of peptides.
- A61P 3/00: Drugs for diabetes treatment.
3.4. Legal Status & Patent Term
- Due to its filing in 2001, the patent's expiration date is approximately 20 years from filing, i.e., around 2021, subject to any terminal disclaimer, patent term adjustments, or extensions.
- As of 2023, the patent is likely expired, opening the space for litigation-free biosimilar or generic entry.
4. Comparative Analysis: Scope & Competitor Landscape
| Patent |
Focus |
Similarities |
Differences |
Strategic Positioning |
| 6,921,528 |
Peptide therapeutics for hyperglycemia |
Core peptide analogs, delivery methods |
Specific peptide sequences, dosage regimens |
Broad coverage of peptide modifications and treatment methods |
| US 7,473,464 |
GLP-1 receptor agonists (e.g., liraglutide) |
Incretin mimetics |
Different peptide sequences, longer half-lives |
Complementary narrower focus; potential licensing |
| US 6,530,390 |
Pramlintide (amylin analog) |
Peptide-based, diabetes treatment |
Different target (amylin vs. GLP-1) |
Near-competition in peptide-based diabetes therapies |
5. Impact on Industry, R&D, and Legal Strategies
- Patent Strengths: Broad claim scope covering peptide analogs, treatment methods, and formulations provided strong barriers around specific classes of diabetes therapeutics.
- Potential Infringements: Competitors developing similar incretin mimetics must navigate these claims carefully, especially prior to patent expiration.
- Strategic Positioning: Eli Lilly’s positioning with this patent set the foundation for later blockbuster drugs; the patent landscape reflects a hybrid of broad and narrow claims aimed at maximizing coverage and legal defensibility.
6. Key Differentiators and Innovations
| Aspect |
Innovation |
Industry Context |
| Peptide Modification |
Amino acid substitutions for stability and receptor affinity |
Enhances pharmacokinetics and efficacy |
| Delivery Systems |
Focus on injectable and controlled-release formulations |
Addresses patient compliance issues |
| Therapeutic Indications |
Hyperglycemia, diabetes, and related conditions |
Tailored to evolving clinical needs |
7. Frequently Asked Questions (FAQs)
Q1: How does Patent 6,921,528 compare to other incretin-based therapies?
A1: It claims specific peptide analogs with modifications designed to improve efficacy, differentiating from earlier, unmodified GLP-1 peptides. Its broad claims provided a strong IP position during the early development of incretin mimetics.
Q2: Are the claims limited to specific peptide sequences?
A2: The independent claims are broad and encompass peptides similar to SEQ ID NO: 1 with certain modifications. Dependent claims specify narrower sequences, providing layered protection.
Q3: When does this patent expire, and what does its expiration mean for the market?
A3: Likely expired around 2021, opening the field for biosimilar development without infringing current rights, increasing market competition.
Q4: How has the patent landscape shifted since this patent was granted?
A4: Post-2005, numerous patents on newer GLP-1 analogs, delivery devices, and combination therapies have emerged, with some overlapping claims, heightening patent landscape complexity.
Q5: What are the legal risks for companies developing similar peptide therapeutics now?
A5: With patent expiration, legal risks diminish. However, competitors must still navigate remaining or patent-protected formulations and delivery methods, especially if patents from other jurisdictions are involved.
8. Conclusions & Actionable Insights
- For Innovators: Building on the broad peptide modifications and formulations claimed in this patent can accelerate development but must respect the expired rights, focusing on novel innovations to avoid infringement.
- For Patent Filers: The strategy exemplified by EL Lilly demonstrates the importance of layered claims—broad core claims supported by narrower dependent claims—to maximize scope and defensive protection.
- For Market Participants: Continuous monitoring of peptide patent landscapes is vital, particularly around expiration dates, to identify entry points for biosimilars or novel therapeutics.
9. References
[1] Eli Lilly and Company, U.S. Patent No. 6,921,528, “Method for Treating Hyperglycemia,” July 26, 2005.
[2] United States Patent and Trademark Office (USPTO) Patent Database.
[3] WIPO Patent Scope Database.
[4] ClinicalTrials.gov for GLP-1 and related therapeutics.
[5] World Health Organization. International Classification of Diseases (ICD-10) code for diabetes mellitus.
Key Takeaways
- Patent 6,921,528 offered broad claims on peptide analogs and associated treatment methods, protecting Eli Lilly’s position in the early 2000s incretin therapeutics market.
- Its expiration likely facilitated market entry for competitors developing medicines with similar peptide structures.
- An understanding of the scope and claims helps stakeholders avoid infringement, foster innovation, and strategize around patent expiry timelines.
- The evolving patent landscape highlights the importance of layered, specific claims to defend novel innovations effectively.
This comprehensive analysis aims to empower business professionals, patent strategists, and R&D leaders with critical insights into the patent landscape surrounding the molecule class and therapeutic approaches encapsulated in U.S. Patent 6,921,528.
More… ↓
⤷ Start Trial
|
